Highest-materiality recent filing
Silo Pharma raises $4M in private placement; warrants could add $7.7M
Issued 619,965 shares (or pre-funded warrants) at $6.452/share plus Series A-3 and A-4 warrants.
Silo Pharma regains compliance with Nasdaq minimum bid price rule
Received Nasdaq confirmation on June 17, 2026, that it regained compliance with Listing Rule 5550(a)(2).
Silo Pharma announces 1-for-15 reverse stock split effective June 2, 2026
Every 15 shares of common stock combined into 1 share; par value unchanged at $0.0001.
Silo Pharma announces 1-for-15 reverse stock split effective June 2, 2026
1-for-15 reverse split effective 4:01 pm ET on June 2, 2026; post-split trading begins June 3 under same symbol SILO.
Silo Pharma acquires QwikAgents software and domains for 2.1M shares
Asset purchase agreement with Many Ads Inc. for QwikAgents web application and domain names (qwikagents.com, .ai, .co).
Silo Pharma authorizes $1M buyback; pays IR consultant 848k shares
Board approved stock repurchase program up to $1 million of common stock.
Silo Pharma receives Nasdaq extension until June 22, 2026 to regain minimum bid price compliance
Company failed to meet $1.00 minimum bid price requirement by initial Dec. 24, 2025 deadline.
Silo Pharma shareholders approve 1:2-1:20 reverse split and increase equity plan shares to 1.4M
Reverse split authorized at ratio from 1-for-2 to 1-for-20, board may implement before October 24, 2026.
Silo Pharma closes $2.5M registered direct offering of common stock and warrants
Sold 2,857,143 shares at $0.875/share; gross proceeds ~$2.5 million.
Silo Pharma launches crypto treasury strategy; appoints Corwin Yu to advisory board
Board established Crypto Advisory Board (up to 3 members); appointed Corwin Yu as first member.
Silo Pharma acquires crypto software and domain assets for 750,000 shares
Acquired software for r2crypto.com and domain names socialscan.info, coinfeel.net, r2crypto.com from MAVS Holdings LLC.
Silo Pharma terminates UMB license, enters evaluation license and option for CNS-homing peptides
Terminates 2021 Master License Agreement with University of Maryland, Baltimore effective June 30, 2025.
Silo Pharma receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notified Silo of non-compliance with minimum bid price rule after 30 consecutive business days below $1.00, from May 14 to June 26, 2025.
Silo Pharma closes $2M public offering of common stock and warrants
Offered 3,333,338 shares (or pre-funded warrants) plus Series A-1 and A-2 warrants for up to 3,333,338 shares each.
Silo Pharma provides pipeline update; pre-IND for SPC-15 pending FDA guidance
Lead asset SPC-15 (intranasal PTSD treatment) aims for first-in-human trials after FDA pre-IND feedback.
Silo Pharma receives US patent for stress-induced affective disorder prophylactics
USPTO granted Patent No. 12,239,614 for exclusively licensed Columbia University technology.
Silo Pharma issues shareholder letter: SPC-15 IND expected 2025, SP-26 animal studies in early 2025
IND submission for SPC-15 intranasal PTSD treatment expected in 2025; Phase 1 trial to follow upon FDA approval.
Silo Pharma shareholders re-elect board, ratify auditor, approve say-on-pay
All four director nominees re-elected: Weisblum (578,427 for, 72,755 withhold), Linsley, Munoz, Pavell.
Silo Pharma postpones 2024 annual meeting to Dec 20, 2024; new record date Nov 12
Annual meeting originally Nov 12, 2024, now rescheduled to Dec 20, 2024.
Silo Pharma posts investor presentation for Sep 2024 conference; notes SPC-15 pre-IND submitted
Presentation used at H.C. Wainwright 26th Annual Global Investment Conference on Sep 10, 2024.
Silo Pharma raises $2.1M in registered direct offering of 763,638 shares at $2.75
Gross proceeds ~$2.1M from sale of 763,638 common shares at $2.75 each.
Silo Pharma enters exclusive global license with Columbia University for PTSD candidate SPC-15
License covers patents and technical info for SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD.
Silo Pharma amends license milestones with University of Maryland, Baltimore
Fourth Amendment replaces Schedule C diligence milestones under the Master License Agreement.
Silo Pharma raises $2M in registered direct offering with warrants
Sold 917,432 shares at $2.18/share and issued warrants for 917,432 shares at $2.06 exercise price.
Silo Pharma submits pre-IND to FDA for SPC-15 intranasal PTSD treatment
SPC-15 is an intranasal prophylactic treatment for PTSD and stress-induced anxiety disorder.
Silo Pharma extends stock repurchase program to April 30, 2024
Board approved extension of $1.0M repurchase program until April 30, 2024.
Lead program SPC-15 (intranasal PTSD prophylactic) Pre-IND submission planned by end of Q2 2024.
Silo Pharma extends stock repurchase program of up to $1M through March 31, 2024
Board approved extension of stock repurchase program authorizing up to $1M in common stock purchases until March 31, 2024.
Silo Pharma extends stock repurchase program up to $1M through March 31, 2024
Board extended stock repurchase program through March 31, 2024.
Silo Pharma reincorporates from Delaware to Nevada, effective December 19, 2023
Reincorporation completed via Plan of Conversion approved by stockholders on Dec 4/11, 2023.
Silo Pharma shareholders approve reincorporation from Delaware to Nevada
Proposal 3 approved with 1,589,197 For, 43,858 Against, 10,276 Abstain, 40,875 Broker Non-Vote.
Silo Pharma reduces authorized shares to 100M, adjourns annual meeting for Nevada reincorporation
Shareholders approved decrease of authorized common stock from 500M to 100M; Certificate of Amendment filed Dec 4, 2023.
Silo Pharma shareholders approve 80% authorized share reduction and equity plan at annual meeting
Four directors elected: Weisblum, Linsley, Muñoz, Pavell (1.45M-1.45M for each).
Silo Pharma amends U. Maryland license, sets new development milestones through 2033
Third Amendment to Master License Agreement replaces entire diligence milestone schedule (Schedule C).
Silo Pharma files PCT patent for Alzheimer's treatment using prucalopride and ketamine
PCT patent application filed on August 25, 2023, for methods treating Alzheimer's disease.
Term of Commercial Evaluation and License Agreement extended to September 30, 2023.
Silo Pharma files provisional patent for ketamine pain management (SP-26) targeting fibromyalgia.
Provisional patent titled 'Methods and Compositions for Pain Management' covers chronic pain including fibromyalgia.
Silo Pharma files provisional patent for CNS-homing peptides to treat Alzheimer's
Filed provisional patent for CNS-homing peptides targeting Alzheimer's disease and dementia.
Silo Pharma receives U.S. patent covering SPC-15 for stress-induced affective disorders
USPTO issued U.S. Patent 11,491,120 for SPC-15, a prophylactic using ketamine for anxiety and PTSD in females.
Silo Pharma announces board-authorized stock repurchase program up to $1M
Board authorized repurchase of up to $1M of common stock in open market or privately negotiated transactions.
Silo Pharma transmits three PCT patent applications to USPTO for psilocybin delivery
Received notice of successful transmission to USPTO for three PCT patent applications.
Silo Pharma provides pipeline update, cites $12M cash and zero debt
Cash over $12M, no debt, listed on Nasdaq; pursuing 505(b)(2) pathway for several assets.
Silo Pharma hires Eric Weisblum as CEO with $350K salary, extends Columbia research pact
Eric Weisblum appointed CEO; base salary $350K/yr, signing bonus $100K, annual bonus up to $350K.
Closed underwritten offering of 1,150,000 shares (incl. full over-allotment) at $5.00/share, gross proceeds $5.75M, net ~$4.83M.
Silo Pharma implements 1-for-50 reverse stock split in preparation for Nasdaq uplisting
Reverse split at ratio of 1-for-50 effective 4:01 p.m. ET on September 14, 2022.
Silo Pharma shareholders approve reverse stock split of 1-for-5 to 1-for-50
Shareholders granted Board discretion to effect a reverse split at a ratio between 1:5 and 1:50.
Silo Pharma corrects special meeting date to Friday March 11, 2022
Special meeting of stockholders set for Friday, March 11, 2022 at 11:00 a.m. ET at 560 Sylvan Ave, Englewood Cliffs, NJ.
Silo Pharma sets director compensation: $25k retainer + options, $0.1460 strike, one-year vest
Non-employee directors receive $25,000 cash retainer plus 177,233 option shares at $0.1460, one-year cliff vest.
Silo Pharma partners with Columbia University on ketamine-based Alzheimer's therapeutic
Sponsored research agreement with Columbia University to develop ketamine treatment for Alzheimer's disease.
Silo Pharma sells 1M shares of DatChat for ~$6.6M
Sold 1,000,000 shares of DatChat, Inc. for aggregate proceeds of approximately $6.6 million.
On October 12, 2022, the Company entered into an employment agreement with Eric Weisblum (the “Weisblum Employment Agreement”)
On September 27, 2022, the Board appointed Daniel Ryweck as Chief Financial Officer of the Company
On September 27, 2022, Eric Weisblum resigned as our Chief Financial Officer.
On September 27, 2022, the Company’s Board of Directors (the “Board”) appointed Jeff Pavell as a member of the Board.
Max materiality 0.90 · Median 0.50 · Most common event other_material